Here are some of our editor’s top picks from the conference:
Diego Garcia-Borreguero, MD, PhD
Dopamine agonists in RLS: Consequences of long-term use and alternative options
In this interview, Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, provided us with a comprehensive review of restless legs syndrome (RLS) treatment, including consequences of long-term treatment with dopamine agonists and potential alternative treatment pathways.
Emmanuel Mignot, MD, PhD
An update on TAK-861 and orexin agonists in narcolepsy type 1
Emmanuel Mignot, MD, PhD, Stanford University School of Medicine, Palo Alto, CA, talked us through the clinical development of TAK-861, an investigational oral orexin receptor 2 agonist, which has recently entered Phase 3 clinical studies for narcolepsy type 1 (NT1; NCT06470828).
Karen Spruyt, PhD
The central role of sleep in the overall health & development of pediatric populations
Leading pediatric sleep expert, Karen Spruyt, PhD, Université Paris Cité, INSERM, NeuroDiderot, Paris, France, spoke about the role of sleep in the overall health and development of pediatric populations, and how an instability of sleep may be associated with cognitive underperformance as well as social, behavioral, and emotional issues.
Stay in the loop and get notified when our Sleep Europe congress coverage goes live by signing up to the VJNeurology newsletter here .
